Cyclic A-beta Peptide for Selective Oligomer Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibodies targeting Amyloid-beta (A-beta) peptides are not effectively selective for A-beta oligomers, which are toxic and elusive due to their conformational plasticity and low concentration, making them difficult to target specifically.
Innovation Solution
Development of cyclic compounds comprising specific A-beta peptide sequences like QKLV, which are selectively exposed in oligomeric forms, and antibodies specifically binding these cyclic compounds, demonstrating higher affinity for oligomers over monomers and fibrils.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibodies are used to target A-beta, then they can bind to A-beta peptides, but they lack selectivity for toxic oligomers and bind non-specifically to monomers and fibrils
Solution Approach 1:
The patent applies local quality by designing cyclic peptides that present specific local conformations of the QKLV epitope (residues 15-18) that are selectively exposed on oligomeric surfaces. The cyclic structure creates a localized conformational epitope that is distinct from the linear peptide structure, allowing antibodies to distinguish oligomers from monomers and fibrils based on this local structural feature.
Solution Approach 2:
The patent employs parameter changes by cyclizing the peptide backbone to constrain the QKLV sequence into specific three-dimensional conformations. This structural parameter change creates epitopes with distinct spatial arrangements that are selectively recognized by antibodies, enabling differentiation between oligomeric and other A-beta species based on conformational parameters rather than just sequence.
2Reliability
If A-beta oligomers are targeted, then therapeutic effect can be achieved, but oligomers are elusive due to low concentration and conformational plasticity
Solution Approach 1:
The patent applies preliminary action by pre-organizing the QKLV peptide sequence into cyclic structures with defined conformations before antibody binding. This pre-conformational arrangement creates stable, detectable epitopes that enhance the visibility and detectability of oligomers, allowing antibodies to bind more reliably to the pre-formed cyclic epitopes rather than searching through conformational plasticity.
3Reliability
If cyclic compounds are designed to bind oligomers selectively, then specificity increases, but the complexity of compound design and antibody generation increases
Solution Approach 1:
The patent applies segmentation by focusing on a specific segment (residues 15-18, QKLV) of the A-beta peptide rather than attempting to design cyclic structures encompassing the entire peptide. This segmentation approach simplifies the design process by concentrating on a critical epitopic segment that, when cyclized, provides sufficient conformational specificity for oligomer recognition without requiring complex full-length cyclic designs.
Data Source
AI summary
The disclosure pertains to epitopes identified in A-beta including conformational epitopes, antibodies thereto and methods of making and using immunogens and antibodies specific thereto.